Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma

Lung Cancer

Volumn 84, Issue 3, 2014, Pages 271-274

  Zauderer, Marjorie G ^a   Kass, Samantha L ^b   Woo, Kaitlin ^c   Sima, Camelia S ^c   Ginsberg, Michelle S ^c   Krug, Lee M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Gemcitabine; Mesothelioma; Vinorelbine

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE; PEMETREXED; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MESOTHELIOMA; MORTALITY; PLEURAL NEOPLASMS; PROCEDURES; RETROSPECTIVE STUDY; SALVAGE THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; VINBLASTINE;

EID: 84901916245     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.03.006     Document Type: Article

References (14)

1. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644.
2. Stebbing J., Powles T., McPherson K., Shamash J., Wells P., Sheaff M.T., et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009, 63(1):94-97.
3. Muers M.F., Stephens R.J., Fisher P., Darlison L., Higgs C.M., Lowry E., et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008, 371(9625):1685-1694.
4. Zucali P.A., Perrino M., Lorenzi E., Ceresoli G.L., De Vincenzo F., Simonelli M., et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer 2013, [Epub ahead of print]. 10.1016/j.lungcan.2013.11.011.
5. van Meerbeeck J.P., Baas P., Debruyne C., Groen H.J., Manegold C., Ardizzoni A., et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999, 85(12):2577-2582.
6. Manegold C., Symanowski J., Gatzemeier U., Reck M., von Pawel J., Kortsik C., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005, 16(6):923-927.
7. Kindler H.L., Millard F., Herndon J.E., Vogelzang N.J., Suzuki Y., Green M.R. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001, 31(2-3):311-317.
8. Nowak A.K., Byrne M.J., Williamson R., Ryan G., Segal A., Fielding D., et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002, 87(5):491-496.
9. van Haarst J.M., Baas P., Manegold C., Schouwink J.H., Burgers J.A., de Bruin H.G., et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002, 86(3):342-345.
10. Byrne M.J., Davidson J.A., Musk A.W., Dewar J., van Hazel G., Buck M., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17(1):25-30.
11. Zucali P.A., Ceresoli G.L., Garassino I., De Vincenzo F., Cavina R., Campagnoli E., et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008, 112(7):1555-1561.
12. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15(2):257-260.
13. Krug L.M., Kindler H., Calvert C., Manegold C., Tsao A.S., Fennell D., et al. VANTAGE 014: vorinostat (V) in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial. Eur J Cancer 2011, 47(2):2-3.
14. Busacca S., Sheaff M., Arthur K., Gray S.G., O'Byrne K.J., Richard D.J., et al. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol 2012, 227(2):200-208.